Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

18 Jan 2005 07:00

Embargoed Release: 07:00hrs Tuesday 18 January 2005 SOPHEON PLC (`Sopheon' or `the Company') TRADING UPDATE Sopheon plc, the international provider of solutions that improve the returnfrom innovation and product development, announces that the Company's EBITDAresult for the final quarter of 2004 is expected to be positive, and that theconsolidated annual EBITDA loss for 2004 is expected to be in line with brokerforecasts of ‚£1.15m (2003 - ‚£4.07m). Sales growth over the prior year achievedin Sopheon's continuing software business is substantial, however, totalreported revenues for 2004 are expected to be moderately below brokerforecasts. This expectation is due in part to the weakness in the dollar duringthe later stages of the year. Nevertheless the overall effect of the weakdollar is expected to have been marginally positive, due to the fact that alarge portion of Sopheon's costs are dollar denominated.As indicated in earlier announcements, the final quarter performance wasdependent on completion of major sales in December. Sopheon was successful insigning three such orders. Each customer is a global leader in its respectiveindustry and a widely recognized name, and two of the transactions includedlicense fees of around $600,000. Apart from their financial and brand value,these deals underpin Sopheon's credentials in two industries with significantidentified potential: fast-moving consumer goods (FMCG) and financial services.Several other transactions were concluded during the quarter, primarily in thechemicals sector, where we already have a substantial base of customers. Wecontinue to focus on pipeline creation and extending business with existingcustomers. An excellent example of the latter is BASF. Developed as a customerthrough one of Sopheon's distribution partners, BASF began implementation ofAccolade a year ago. Our relationship with this chemicals industry leader hasgrown rapidly since then, and BASF is now one of four Sopheon clients that havecontracted for 2000 or more Accolade seat-licenses.Sopheon made important progress in 2004 in positioning itself for the longerterm by securing partnerships on two fronts: strategic alliances in keymarkets, and distribution partners in geographical areas outside the Company'sexisting sphere of operations. As a result of this effort we are part ofMicrosoft's Collaborative Product Development initiative. Since announcement ofthe program in October, Microsoft and Sopheon have been working together toenhance and promote the integration of their technologies. To enabledevelopment efforts arising from this and other initiatives, and with supportfrom Microsoft, Sopheon implemented a controlled expansion in R&D resources,recruiting into our Denver development center. During the year Sopheon alsoundertook a successful balance sheet restructuring, and continues to haveaccess to the group's ¢â€š¬10m equity line, of which over 90% remains untapped.Financial expectations noted above are subject to the completion of theyear-end financial close process. Consistent with prior years, Sopheon plans toissue its 2004 preliminary results around the end of March.Sopheon's Chairman, Barry Mence said:"Achieving a positive quarterly result is an important milestone for Sopheon.We are focused on the challenge of maintaining this momentum into the firsthalf of 2005, encouraged by our recent successes and the opportunities that arebuilding through our strategic relationships."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Barbara Jansen Citigate First Financial Tel : + 31 (0) 205 754 010About SopheonSopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product development. TheSopheon Accolade‚® product development system automates gate- or phase-basedproduct development (PD) processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time to market. Sopheon is listed on the AIM market of the LondonStock Exchange and on the Euronext in the Netherlands. For more information,please visit www.sopheon.com.END
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.